Personalized vaccine may extend survival of glioblastoma patients:
MRI scans show a patient with a brain tumor. A personalized vaccine targeting the deadly brain cancer glioblastoma may improve survival for some patients, according to a new study. Washington University School of Medicine in St. Louis was one of 80 clinical trial sites worldwide testing the vaccine.
Most people with the deadly brain cancer glioblastoma die less than 18 months after diagnosis. But a multicenter clinical trial of a personalized vaccine that targets the aggressive cancer has indicated improved survival rates for such patients.